Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > BUSINESS
BUSINESS
- Biogen Japan Expects Continued Growth Past 2020 through Major New Drugs
August 11, 2015
- Long-Acting Injectable Version of Abilify Entering Accelerated Growth Phase: Pres. Higuchi of Otsuka Holdings
August 11, 2015
- Sublingual Immunotherapy Tablet for Pollinosis Shows Efficacy in PII/PIII Study in Japan: Torii
August 11, 2015
- Denki Kagaku Kogyo to Acquire Germany’s Biopharma Icon Genetics
August 11, 2015
- Drug Wholesalers Suffer 1st Sales Drop since 1997
August 10, 2015
- Sumitomo Dainippon Will Be Able to Cover the Loss of Long-Listed Drug Sales: President
August 10, 2015
- Pharmaceutical Sales Down 2.4% in 1st Half Due to Loss of Patent Protection for Abilify in US: Otsuka Holdings
August 10, 2015
- Sosei’s UK Subsidiary, AZ Partner for Development of Cancer Immunotherapies
August 10, 2015
- ASCO Immunotherapy Roundup - 5: Merck & Co. Discovers New Biomarkers for Keytruda
August 7, 2015
- Sanofi Files NDA for Hypercholesterolemia Treatment Alirocumab in Japan
August 7, 2015
- Pfizer Japan Pays 14.8 Billion Yen to Doctors, Medical Institutions in FY2014 under Transparency Guidelines
August 7, 2015
- Japan Pharma Market Up 7.9% in April-June 2015: IMS
August 6, 2015
- 14-Day Limit on Prescriptions Considered Unnecessary from a Safety Standpoint in the US and Europe: Pfizer Pres. Umeda
August 6, 2015
- 80% Generic Target “Completely Unexpected,” and Makes Stable Growth in Japan Market Difficult: Pfizer Pres.
August 6, 2015
- AZ Japan Sales Up 2% to US$977 Million in 1st Half of 2015
August 6, 2015
- Astellas Transfers Muscle Relaxant Suxamethonium to Maruishi on Oct. 1
August 6, 2015
- Naldemedine Demonstrates Favorable Results in 3 PIII Efficacy Studies for Opioid-Induced Constipation: Shionogi
August 5, 2015
- Santen Transfers Anti-Rheumatic Business to Ayumi Pharmaceutical
August 5, 2015
- GSK Suspends Shipment of Anti-MRSA Agent Bactroban
August 5, 2015
- Daiichi Sankyo to Submit 4 Products for Approval in Japan and Overseas through FY2018
August 4, 2015
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…